Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT04414566 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: June 1, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare induction chemotherapy (TPF or GP) plus radiotherapy alone with induction chemotherapy plus concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

NCT ID: NCT04394091 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients

Start date: May 20, 2020
Phase:
Study type: Observational [Patient Registry]

NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and high-sensitivity PET/CT protocol simultaneously in the follow-up of Locally Advanced Nasopharyngeal Carcinoma. Hence we establish this prospective cohort study.

NCT ID: NCT04385654 Not yet recruiting - Advanced Cancer Clinical Trials

Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma

Start date: June 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of toripalimab combined with axitinib as neoadjuvant therapy for advanced/metastatic non-clear cell renal cell carcinoma

NCT ID: NCT04352894 Not yet recruiting - Gastric Cancer Clinical Trials

Intraoperative ICG Fluorescence Imaging for Peritoneal Carcinomatosis Detection

Start date: September 2020
Phase: N/A
Study type: Interventional

Background. Peritoneal carcinomatosis is a frequent and deadly localization of gastric cancer. Available imaging techniques have a low accuracy in detecting small peritoneal nodules, and direct laparoscopic visualization may fail too. A more accurate staging technique would be advantageous for individualization of therapeutic path. Indocyanine Green (ICG) fluorescence imaging has been reported as a tool for visualizing small peritoneal seedings due to the "enhanced permeability and retention" (EPR) effect of cancer nodules. Aim. To explore the feasibility and effectiveness of fluorescence-enhanced peritoneal carcinomatosis detection in patients with gastric cancer undergoing staging laparoscopy. Methods. This prospective, multicentric, single arm study will include patients with gastric cancer, without a radiological suspicion of peritoneal carcinomatosis, undergoing staging laparoscopy. An intravenous injection of ICG is given at different dosage and at different timepoints before the intervention. During the staging laparoscopy, the abdominal cavity exploration is performed using standard white-light, and subsequently using fluorescence imaging. Suspicious nodules are harvested, until a maximum of 5 per patient, and sent for definitive histological examination. Peritoneal washing is also harvested for cytologic assessment in all cases. The eventual benefit of fluorescence imaging in terms of additional peritoneal lesions that were not detected during standard white-light imaging is evaluated. Discussion. This study will establish if fluorescence imaging increases sensitivity and/or specificity of staging laparoscopy in detecting peritoneal carcinomatosis from gastric cancer. Improved accuracy may translate in better care path selection.

NCT ID: NCT04351282 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Primary metastatic NPC patients received chemotherapy± immunotherapy, radiation for primary tumors and SBRT for metastatic lesions.

NCT ID: NCT04344158 Not yet recruiting - Clinical trials for Advanced Hepatocellular Carcinoma (HCC)

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Start date: May 1, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105 injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib, with 2:1 random ratio. Every 21 days is a treatment cycle.

NCT ID: NCT04331743 Not yet recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC

Start date: June 5, 2021
Phase: Phase 1
Study type: Interventional

This is a dose escalation study based on 3+3 design with the aim to establish MTD and provide RP2D. PLM60 is to administered by multi-cycle intravenous infusion.

NCT ID: NCT04319484 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

LLTHVV
Start date: May 2, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to observe the efficacy and safety of lenvatinib in preventing recurrence of hepatocellular carcinoma patients with portal vein tumor thrombus after liver transplantation.

NCT ID: NCT04319471 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of sufficient chemoradiotherapy plus oral capecitabine/S-1 for 1 year in the treatment of oligometastatic Nasopharyngeal Carcinoma

NCT ID: NCT04303975 Not yet recruiting - Clinical trials for Head and Neck Cancer

The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma

Start date: June 2021
Phase:
Study type: Observational

The primary purpose of this study is to explore the association of high sensitivity C-reactive protein (hsCRP) and radiotherapy(RT)-induced toxicity in patients with nasopharyngeal carcinoma. In each patient, hsCRP levels in the pre- and post-RT plasma samples will be measured according to the schedule we set.